Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$301.00 USD

301.00
2,727,143

+4.63 (1.56%)

Updated May 30, 2024 04:00 PM ET

After-Market: $301.01 +0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Amgen (AMGN) Q4 Earnings Top; Repatha Positive in CV Study

Amgen Inc. (AMGN) reported fourth-quarter 2016 earnings of $2.89 per share, beating the Zacks Consensus Estimate of $2.77 by 4.3% .

    Arpita Dutt headshot

    Biotech Stock Roundup: Celgene, Biogen, ABBV Post Q4 Results, Catabasis Falls on DMD Data

    Major highlights this week were earnings results from companies like Celgene (CELG) and pipeline updates.

      Mallinckrodt (MNK) Earnings This Quarter: Stock to Disappoint?

      Mallinckrodt plc (MNK) is set to report results for the quarter ended Dec. 30, 2016 on Feb 7.

        The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Amgen, Valeant Pharmaceuticals International, Celgene and Lexicon Pharmaceuticals

        The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Amgen, Valeant Pharmaceuticals International, Celgene and Lexicon Pharmaceuticals

          Should You Sell Amgen (AMGN) Before Earnings?

          Amgen (AMGN) could be an interesting stock for investors ahead of earnings, as it has a positive ESP and a favorable Zacks Rank.

            Merck Keytruda Gets EU Approval for First-Line Lung Cancer

            Merck & Co., Inc. (MRK) announced that its anti-PD-1 therapy Keytruda has been approved by the European Commission for the first-line treatment of adult patients with metastatic non-small cell lung cancer.

              Madeleine Johnson headshot

              Stock Market Roundup Jan. 31: Nasdaq Rebounds Amid Trump Biotech Meeting

              Following the trend set yesterday, U.S. stocks closed mostly lower on Tuesday but still managed to record monthly gains. Investors continue to weigh the latest policies from the Trump Administration as well as companies' results from the current earnings season.

                Kinjel Shah headshot

                Pfizer (PFE) Q4 Earnings Lag, Sales Top; '17 Sales View Soft

                Pfizer, Inc. (PFE) missed earnings estimates in the fourth quarter.

                  Arpita Dutt headshot

                  4 FDA Decisions to Watch Out for in Feb 2017

                  So far this year, the FDA has approved one drug. Will the pace of drug approvals pick up in February?

                    Pfizer (PFE) Gets Positive CHMP Opinion for Arthritis Drug

                    Pfizer Inc. (PFE) announced that Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion for the company's marketing authorisation application (MAA) for its rheumatoid arthritis (RA) drug, Xeljanz.

                      Amgen Wins Favorable CHMP Opinion for Humira Biosimilar

                      Amgen (AMGN) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion on the company's marketing authorization application (MAA) for ABP 501.

                        Will Amgen (AMGN) Keep the Earnings Streak Alive in Q4?

                        We expect biotech major Amgen Inc. (AMGN) to beat expectations when it reports fourth-quarter 2016 and full-year results on Feb 2.

                          Biogen (BIIB) Q4 Earnings Top Estimates; '17 Sales View Soft

                          Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, reported mixed fourth-quarter 2016.

                            Novartis (NVS) Beats Q4 Earnings, Might Spin-Off Alcon

                            Novartis' (NVS) fourth-quarter 2016 results were mixed with the company beating earnings estimates but missing on revenues. The company has been facing challenging conditions for the past few quarters.

                              Can Amgen (AMGN) Be a Top Choice for Value Investors?

                              Let's see if Amgen Inc. (AMGN) stock is a good choice for value-oriented investors right now from multiple angles.

                                Coherus Offers Positive Phase III Data on Humira Biosimilar

                                Coherus BioSciences, Inc. (CHRS) reported encouraging top-line data from an ongoing part 3, of a phase III study on its biosimilar version of AbbVie Inc.'s (ABBV) Humira (adalimumab), CHS-1420, for the treatment of patients with psoriasis.

                                  Arpita Dutt headshot

                                  Biotech Stock Roundup: ARIAD to be Acquired for $5.2B, Vertex Outlook Falls Short

                                  Several licensing deals and agreements were announced this week including the $5.2 billion ARIAD (ARIA) acquisition.

                                    Amgen: Phase III Data on Hyperparathyroidism Drug Published

                                    Amgen Inc. (AMGN) announced that data from three phase III studies on its pipeline candidate, Parsabiv (etelcalcetide), were published in the Journal of the American Medical Association (JAMA).

                                      Merck: Keytruda+Chemo Gets Priority Review for Lung Cancer

                                      Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) for its anti-PD-1 therapy, Keytruda, has been accepted under priority review by the FDA.

                                        Kite Pharma Inks Deals for CAR T Cell Drug in Japan, China

                                        Kite Pharma (KITE) announced that it has entered into a strategic partnership with Daiichi Sankyo to develop and commercialize axicabtagene ciloleucel (KTE-C19) in Japan.

                                          Amgen Inks Multiple Deals, Offers Update on Repatha Lawsuit

                                          Amgen Inc. (AMGN) announced a new six-year sourcing and supply agreement with DaVita Inc. (DVA) to supply Epogen and Aranesp to meet the latter???s requirements.

                                            Pfizer's Humira Biosimilar Meets Primary Endpoint in Study (Revised)

                                            Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar to AbbVie Inc.'s (ABBV) Humira.

                                              Pfizer's Humira Biosimilar Meets Primary Endpoint in Study

                                              Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar of Humira approved for the treatment of patients with rheumatoid arthritis.

                                                Amgen's Repatha Wins Over Sanofi & Regeneron's Praluent

                                                The U.S. District Court in Delaware granted Amgen, Inc. (AMGN) permanent injunction against infringement by Sanofi and Regeneron of two patents owned by the former for Repatha.

                                                  The Zacks Analyst Blog Highlights: Comcast, Amgen, General Mills, Target and Ford

                                                  The Zacks Analyst Blog Highlights: Comcast, Amgen, General Mills, Target and Ford